RTW Venture Fund Limited Issue of Equity (2201M)
20 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMRTW
RNS Number : 2201M
RTW Venture Fund Limited
20 September 2021
LEI: 549300Q7EXQQH6KF7Z84
20 SEPTEMBER 2021
RTW Venture Fund Limited
(the "Company")
ISSUE OF EQUITY
On 17 September 2021, the Company issued 2,590,105 new ordinary
shares of no par value each (consisting of 2,512,856 shares at a
price of US$1.92 and 77,249 shares at GBP1.39 per share. These
shares rank pari passu with the existing ordinary shares in issue.
The issue price equates to a premium to the net asset value per
share at the time of the transaction.
As a result of this issue, the total number of ordinary shares
in issue now stands at 212,389,138 and the total number of voting
rights in the Company is 212,389,138. There are no shares held in
treasury.
The above figure of 212,389,138 may be used by shareholders as
the denominator for the calculation by which they may determine if
they are required to notify their interest in, or change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
The Company confirms that application for admission will be made
to London Stock Exchange plc and it is expected that admission will
occur at 8:00 a.m. on 24 September 2021.
Stephanie Sirota, who is a Director of the Company, subscribed
for 236,996 New shares. Following this subscription she will hold
1,000,000 shares representing c 0.47% of the enlarged issued
ordinary share capital of the Company.
For further information, please contact:
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225-8885
J.P. Morgan Cazenove +44 (0) 20 7742 4000
William Simmonds
James Bouverat (Sales)
Barclays +44 (0) 20 7623 2323
Tom Swerling
Andrew Tusa
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund
focused on identifying transformative assets with high growth
potential across the biopharmaceutical and medical technology
sectors. Driven by a long-term approach to support innovative
businesses, RTW Venture Fund invests in companies developing
next-generation therapies and technologies that can significantly
improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading US healthcare investment rm with deep scienti c expertise
and a strong track record of supporting companies developing
life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEQVLBFFKLBBBQ
(END) Dow Jones Newswires
September 20, 2021 02:00 ET (06:00 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024